

LABIANA ADVANCES ITS INTERNATIONAL PIPELINE WITH NEW APPROVALS AND LAUNCHES

New European marketing authorizations, a supply agreement covering seven Latin American countries, and two veterinary launches in Spain.

MADRID, SPAIN, September 9, 2026

/EINPresswire.com/ -- Labiana, a

Spanish pharmaceutical group

specializing in the development,

manufacture, and marketing of

medicines for animal and human

health and listed on [BME Growth](#),

continues to advance its international

growth strategy through new

milestones in Europe and Latin

America, both in pipeline development and commercial expansion.



Pharmaceutical vials illustrating Labiana's manufacturing capabilities in animal and human health.

Specifically, as part of the regulatory advancement of its human health pipeline in strategic European Union markets, the company has obtained two marketing authorizations in Sweden

and two additional authorizations in Portugal for medicines containing empagliflozin, an oral antidiabetic agent. It has also obtained two marketing authorizations in the Netherlands for medicines containing octreotide, which is used to treat certain endocrine and digestive disorders. These authorizations represent further progress in the development of Labiana's human health pipeline.

“

These new registrations and launches represent another step forward in the execution of our international growth strategy.”

Sandra Villagrasa, Managing Director of Labiana

Additionally, in collaboration with one of Latin America's leading pharmaceutical companies, Labiana has secured the first five marketing authorizations for [Precyst®](#), its

women's health dietary supplement formulated with D-mannose and cranberry extract. Under this agreement, Labiana will supply the product in seven Latin American countries, marking a

milestone that reinforces its ability to generate value through international agreements and the commercial expansion of its portfolio.

LAUNCH OF TWO INJECTABLE VETERINARY MEDICINES

These regulatory advances in the human health portfolio are complemented by the recent launch in Spain of two veterinary medicines. The first is an injectable formulation containing robenacoxib for the treatment of pain and inflammation in dogs and cats, while the second is an acepromazine-based sedative and preanesthetic for dogs. With these launches, the company continues to expand its commercial portfolio, demonstrating Labiana's ability to translate regulatory development into commercial execution.

These milestones form part of the Group's growth strategy and follow Labiana's strongest financial performance to date in 2025, when the company generated revenue of €75.2 million, up 13.5% year on year, and increased its profit twelvefold to €2.6 million. This performance was driven by growth in both the animal health and human health businesses, as well as by the expansion of the Group's product portfolio and the increasing internationalization of its products.

Currently, the Group's products are marketed in more than 114 countries thanks to its regulatory, industrial, and development capabilities, as well as its international agreements.

According to Sandra Villagrasa, CEO of Labiana, "These new registrations and launches represent another step forward in the execution of our international growth strategy and reflect the strength of our regulatory, industrial, and development capabilities. Securing authorizations in European markets and advancing out-licensing agreements across different markets continue to strengthen Labiana's position as a pharmaceutical group capable of developing, manufacturing, and bringing animal and human health products to scale internationally."

ABOUT LABIANA

[Labiana Health](#) is a leading independent and integrated international platform operating in the animal and human health industries. It has a diversified portfolio of products and businesses and a broad base of top-tier clients with whom it maintains long-standing relationships built on trust.

The Group's products are currently available in more than 150 markets, with proprietary products registered in over 114 countries. This international presence is supported by its two GMP-compliant manufacturing plants in Spain, its subsidiaries in Turkey, Ecuador, and Mexico, its stake in Serbia, its growing network of multinational clients, and its licensing agreements with international distributors for the sale of its proprietary products.

The Group has two distinct yet complementary business lines: contract manufacturing, which

provides stability and revenue visibility, and the development, manufacture, and marketing of proprietary products, which drives growth. The company made its debut on BME Growth in June 2022, becoming the first veterinary company to be listed on this market in Spain.

Cristina Ramos

LABIANA HEALTH, S.A.

comunicacion@labiana.com

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/940814205>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.